| Latest Bristol Myers Sqibb News Headlines |
| Date | Time | Source | |
| 09/29/2008 | 6:22PM | PRNUS | Hagens Berman Sobol Shapiro: Judge Approves Two National Classes in AWP Drug Litigation
AstraZeneca and Bristol-Myers Squibb face separate trials for alleged unfair and deceptive practices relating to cancer fighting drugs.
BOSTON, Sept. 29 /PRNewswire/ -- Two major pharmaceutical companies are facing the fire this week after U.S. District Judge Patti Saris approved two national classes in the Average... More...>> |
| 09/23/2008 | 3:26PM | PRNUS | Icahn Responds to Cornelius
NEW YORK, Sept. 23 /PRNewswire/ -- ImClone Systems Incorporated (NASDAQ: IMCL), announced today that the following letter was sent by Carl Icahn, its Chairman of the Board, to James Cornelius of Bristol-Myers Squibb Company (NYSE:BMY):
September 23, 2008
Mr. James M. Cornelius
Chairman and Chief Executive Office... More...>> |
| 09/19/2008 | 10:25AM | PRNUS | Seven Summits Research Releases Comments on CAT, KO, GM, BMY, and PALM
CHICAGO, Sept. 19 /PRNewswire/ -- Seven Summits Research releases NewsBites on key stocks.
Seven Summits Strategic Investments NewsBites are available to all investors at:
http://www.go7now.com/nb/0919Y (Note: You may have to copy this link into your browser then press the [ENTER] key.)
Today's Seven Summits Strategic... More...>> |
| 09/16/2008 | 12:09PM | PRNUS | First-Ever National Ranking of 'Hot Spots' for Peripheral Artery Disease (P.A.D.) Identifies Cities With Higher Risk of Heart At
- Actress Phylicia Rashad Travels to P.A.D. 'Hot Spots' During P.A.D. Awareness Month to Urge Diagnosed Residents to Seek Treatment -
NEW YORK, Sept. 16 /PRNewswire-FirstCall/ -- According to research conducted by the National Minority Quality Forum (NMQF), Detroit tops the list of P.A.D. "Hot Spots" as the city with... More...>> |
| 09/02/2008 | 6:00AM | PRNUS | Ingenuity Systems Announces Multi-Year Deal With Bristol-Myers Squibb for IPA
REDWOOD CITY, Calif., Sept. 2 /PRNewswire/ -- Ingenuity Systems, the leading provider of information solutions for life science researchers, today announced a multi-year agreement with Bristol-Myers Squibb Company (NYSE:BMY) for use of the Ingenuity Pathways Analysis (IPA) software application. Bristol-Myers Squibb... More...>> |
| 07/11/2008 | 10:47AM | PRNUS | Seven Summits Research Releases Comments on AMAT, CHK, OXY, BMY, and ASH
CHICAGO, July 11 /PRNewswire/ -- Seven Summits Research releases NewsBites on key stocks.
Seven Summits Strategic Investments NewsBites are available to all investors at:
http://www.go7now.com/nb/0711Y (Note: You may have to copy this link into your browser then press the [ENTER] key.)
Today's Seven Summits Strategic... More...>> |
| 06/27/2008 | 10:50AM | PRNUS | Seven Summits Research Releases Comments on FSLR, CHK, BMY, EL, and PALM
CHICAGO, June 27 /PRNewswire/ -- Seven Summits Research releases NewsBites on key stocks.
Seven Summits Strategic Investments NewsBites are available to all investors at:
http://www.go7now.com/nb/0627Y (Note: You may have to copy this link into your browser then press the [ENTER] key.)
Today's Seven Summits Strategic... More...>> |
| 04/30/2008 | 3:00PM | PRNUS | Bristol-Myers Squibb Invites Public to Listen to Webcast of 2008 Annual Meeting
NEW YORK, April 30 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE:BMY) invites investors and the general public to listen to a webcast of its annual meeting with stockholders at 10 a.m. ET on Tuesday, May 6, 2008. In addition to the stockholder and board items to be transacted, senior executives will review... More...>> |
| 04/29/2008 | 8:30AM | PRNUS | Bristol-Myers Squibb Issues $1.6 Billion of Senior Notes
NEW YORK, April 29 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has agreed to sell $1.6 billion of senior unsecured notes: $600 million in aggregate principal amount of 5.450% notes due May 1, 2018 and $1 billion in aggregate principal amount of 6.125% notes due May 1, 2038... More...>> |
| 04/26/2008 | 12:00PM | PRNUS | BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naiv
MILAN, Italy, April 26 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE:BMY) today announced new data from the E.A.R.L.Y. study (ETV-079), in which treatment of antiviral-naive adult chronic hepatitis B patients with BARACLUDE(R) (entecavir) resulted in greater long-term viral load reduction than adefovir... More...>> |
| 04/25/2008 | 4:10PM | PRNUS | Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
PRINCETON, N.J., April 25 /PRNewswire-FirstCall/ -- Medarex, Inc. (NASDAQ:MEDX) and Bristol-Myers Squibb Company (NYSE:BMY) today announced that, after meeting with the U.S. Food and Drug Administration (FDA), the companies will delay the Biologics License Application (BLA) submission for ipilimumab, an investigational... More...>> |
| 04/24/2008 | 10:48AM | PRNUS | Seven Summits Research Releases Comments on SBUX, CVX, AFL, BMY, and ADSK
CHICAGO, April 24 /PRNewswire/ -- Seven Summits Research releases NewsBites on key stocks.
Seven Summits Strategic Investments NewsBites are available to all investors at:
http://www.go7now.com/nb/0424Y (Note: You may have to copy this link into your browser then press the [ENTER] key.)
Today's Seven Summits Strategic... More...>> |
| 04/24/2008 | 7:30AM | PRNUS | Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company
- Reports Broad-Based Net Sales Growth of 20% from Continuing Operations Driven by Strong Performance of Pharmaceutical Business
NEW YORK, April 24 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE:BMY) today reported strong double-digit net sales growth and solid earnings growth for the first quarter... More...>> |
| 04/17/2008 | 12:00PM | PRNUS | Bristol-Myers Squibb to Announce Results for the First Quarter of 2008 on April 24
NEW YORK, April 17 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the first quarter of 2008 on Thursday, April 24. During a 10:30 a.m. (ET) conference call on April 24, company executives will review financial information and will address inquiries from investors and analysts.
Investors... More...>> |
| 04/08/2008 | 3:15PM | PRNUS | U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile
- ORENCIA is a First-in-Class Biologic Treatment Option Now Available for Use in Pediatric Patients with JIA(1,2) -
PRINCETON, N.J., April 8, 2008 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved ORENCIA(R) (abatacept) for... More...>> |
| 04/08/2008 | 8:00AM | PRNUS | BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR D
Isis To Receive $2 Million Milestone Payment
CARLSBAD, Calif., April 8, 2008 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) announced today that Bristol-Myers Squibb Company (NYSE:BMY) has selected a compound from the companies' collaboration as a development candidate. As a result, Isis will receive... More...>> |
| 04/08/2008 | 7:00AM | PRNUS | Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
WALTHAM, Mass., April 8, 2008 /PRNewswire-FirstCall/ -- Repligen Corporation (NASDAQ:RGEN) announced today that it has reached a settlement with Bristol-Myers Squibb Company (NYSE:BMY) in its lawsuit alleging infringement of U.S. Patent No. 6,685,941 ("the '941 patent"), based on Bristol-Myers Squibb's sale of Orencia(R... More...>> |
| 03/24/2008 | 4:07PM | PRNUS | /C O R R E C T I O N -- Bristol-Myers Squibb Company/
In the news release, BARACLUDE(R) (Entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-Naive Chronic Hepatitis B Patients, issued earlier today by Bristol-Myers Squibb Company (NYSE:BMY) over PR Newswire, we are advised by the company that in the "Lamivudine-refractory... More...>> |
| 03/24/2008 | 8:00AM | PRNUS | BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-
- Data Indicate Pre-existing Lamivudine Resistance Predisposes Patients to Higher Rates of BARACLUDE Resistance -
PRINCETON, N.J., March 24 /PRNewswire-FirstCall/ -- New BARACLUDE(R) (entecavir) data presented today demonstrated a continued low incidence of resistance in nucleoside-naive patients through five years... More...>> |
| 03/17/2008 | 9:00AM | PRNUS | Bristol-Myers Squibb to Present at Healthcare Conferences
NEW YORK, March 17 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE:BMY) will present at the Cowen and Company 28th Annual Health Care Conference today. Brian Daniels, M.D., senior vice president, Global Development, will make a formal presentation about the company at 1:45 p.m. ET today.
Bristol-Myers... More...>> |